RYTM News and Press, Rhythm Pharmaceuticals Inc. From 08/02/22

Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Context Therapeutics CNTX +13% . Rhythm Pharmaceuticals RYTM +13% . Harmony Biosciences HRMY +10% . Nautilus Biotechnology NAUT +9% . Losers: Ontrak OTRK -43% . Phathom Pharmaceutical...

The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q2 GAAP EPS of -$0.89 beats by $0.06 . Revenue of $2.31M (+755.6% Y/Y) misses by $0.26M . For further details see: Rhythm Pharmaceuticals GAAP EPS of -$0.89 beats by $0.06, revenue of $2.31M misses by...

-- Received FDA approval for IMCIVREE ® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a strong start with more than 50 IMCIVREE prescriptions written for patients with BBS in first six weeks since FDA ...

RYTM got its third approval in June. The company is generating some revenue. They look set to expand labels for their only asset. Since my previous coverage of Rhythm Pharma ( RYTM ), the stock has grown 50% on the back of an FDA approval of IMCIVREE (setmelanotide) ...

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open. The consensus EPS Estimate is -$1.03 (-47.1% Y/Y) and the consensus Revenue Estimate is $2.57M (+851.9% Y/Y). Over the last 3 months, EPS es...

BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...

A committee of the European Medicines Agency (EMA) recommended the expanded approval of Rhythm Pharmaceuticals' ( NASDAQ: RYTM ) Imcivree (setmelanotide) to include the treatment of obesity and control of hunger in patients six years of age and older with genetic...

-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyper...

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...